香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2025年半年度報告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月22日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 上海昊海生物科技股份有限公司2025 年半年度报告 公司代码 ...

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has a current stock price of 56.75 yuan, with a rolling PE ratio of 31.94, marking a new low in 94 days, and a total market capitalization of 13.199 billion yuan [1] Company Summary - Haohai Biological specializes in the research, production, and sales of medical devices and pharmaceuticals, with key products including ophthalmic viscoelastic devices, artificial lenses, optical materials, hyaluronic acid, and medical chitosan [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.312 million yuan, down 7.41%, with a gross profit margin of 69.52% [1] Industry Summary - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning Haohai Biological at 61st place within the industry [2] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Haohai Biological Technology Co., Ltd. in the medical device industry [1][2] - As of August 15, Haohai's stock closed at 55.18 yuan, with a rolling PE ratio of 31.06 times and a total market capitalization of 12.834 billion yuan [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Haohai at the 60th position in the industry ranking [1][2] Group 2 - As of February 29, 2020, Haohai had 7,605 shareholders, an increase of 918 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business includes the research, production, and sales of medical devices and pharmaceuticals, with key products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1] - In the latest quarterly report for Q1 2025, Haohai reported revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41%, with a gross profit margin of 69.52% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aibo Medical, which closed at 78.7 yuan with a PE ratio of 40.26, marking a new low in 13 days, and a total market capitalization of 15.221 billion yuan [1] - Aibo Medical ranks 78th in the medical device industry based on PE ratio, with the industry average at 56.56 and the median at 39.76 [1][2] - As of March 31, 2025, Aibo Medical has 9,729 shareholders, a decrease of 94 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Aibo Medical specializes in the research, production, sales, and related services of ophthalmic medical devices, with key products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] - In the latest quarterly report for Q1 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.558 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross margin of 64.60% [1]

Group 1 - The core viewpoint of the article highlights the performance and valuation of Aibo Medical, which closed at 79.1 yuan, up 9.30%, with a rolling PE ratio of 40.47, marking a new low in 53 days, and a total market capitalization of 15.298 billion yuan [1] - Aibo Medical ranks 80th in the medical device industry based on PE ratio, with the industry average at 54.56 and the median at 37.54 [1] - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Aibo Medical focuses on the research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] - The latest quarterly report for Q1 2025 shows Aibo Medical achieved a revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.558 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross margin of 64.60% [1]

Core Insights - The Sci-Tech Innovation Board (STAR Market) has evolved from a reform "testbed" to a highland for technological innovation, with a focus on six strategic emerging industries, achieving a total of 588 listed companies and a market capitalization exceeding 6.8 trillion yuan by June 2025 [1][2] Industry Overview - The STAR Market is particularly concentrated in the integrated circuit and pharmaceutical sectors, with 119 and 113 listed companies respectively, making it a major listing venue globally outside the US and Hong Kong [2] - The introduction of the "Eight Measures" has further stimulated resource allocation and industrial vitality in these sectors [2] Company Performance - Union Medical (688271.SH) raised 10.988 billion yuan during its IPO in August 2022, using the funds to enhance global expansion and production capacity for high-end medical imaging equipment [3] - The capital raised has significantly supported Union Medical in achieving breakthroughs in core technologies and establishing a complete self-research system for key components [3][4] - Aibo Medical (688050.SH) has experienced continuous revenue and net profit growth since its listing in 2020, with a compound annual growth rate of 39.56% in R&D investment from 2022 to 2024 [5][6] Market Dynamics - The STAR Market has become a key driver of domestic pharmaceutical innovation, with 33 globally new Class 1 drugs launched by STAR-listed companies since 2018, accounting for approximately 14% of all domestic Class 1 drugs approved during the same period [7] - In the integrated circuit sector, STAR-listed companies achieved a combined revenue of 72.182 billion yuan in Q1 2025, representing a 24% year-on-year increase, and a net profit of 4.479 billion yuan, up 73% [7][8] Strategic Developments - Companies like Longxin Zhongke (688047.SH) have accelerated their R&D iterations post-listing, increasing their annual new chip releases from 1-2 to 4-5 [8][9] - The ongoing push for domestic chip production is creating rapid development opportunities for chip companies, with significant growth in revenue and profitability observed [9][10] M&A Activity - The STAR Market encourages mergers and acquisitions as a means for companies to achieve external growth, with several notable cases emerging in 2023 [10][11] - Companies are actively seeking M&A opportunities to enhance their technological capabilities and market presence, with a focus on strategic alignment and operational synergy [11][12]

Core Viewpoint - The event on June 6, 2025, marks the 30th National "Eye Care Day," focusing on public awareness of common eye diseases and their prevention and treatment strategies, particularly in the context of an aging population [1][4]. Group 1: Common Eye Diseases - Cataracts, glaucoma, age-related macular degeneration, presbyopia, and dry eye syndrome are prevalent eye diseases that significantly impact quality of life [1][4]. - Cataracts are linked to natural aging and UV exposure, with sunglasses recommended as a preventive measure [3]. - Glaucoma results from increased intraocular pressure leading to irreversible damage to the optic nerve, often associated with stress and irregular lifestyles [3]. Group 2: Prevention and Treatment Strategies - Preventive measures for glaucoma include self-care, stress management, aerobic exercise, and various treatment options such as medication, laser therapy, and surgery [3]. - Dietary recommendations for age-related macular degeneration include consuming foods rich in lutein, such as carrots and corn, alongside mainstream treatment options like medication and surgery [3]. - Presbyopia, a functional disease due to aging, can be managed with appropriate eyewear, medication, and surgical interventions [3]. Group 3: Public Awareness and Education - There is a need for increased public awareness regarding the scientific understanding of these eye diseases, emphasizing the importance of early detection, intervention, and treatment to prevent irreversible damage [4].

Summary of the Conference Call Records Industry Overview: Ophthalmic Consumables Key Points on Cataract Surgery Market - **Cataract Surgery Volume Recovery**: In the first five months of 2025, cataract surgeries showed signs of recovery, with some hospitals experiencing a growth of 20%-25% and a slight increase in unit prices compared to 2024. The overall performance for the first half of 2025 is expected to be strong, with stable outpatient volumes and average transaction prices anticipated for the year [1][3] - **Seasonal Trends**: Cataract surgeries have two peak periods annually: from the sixth day after the Spring Festival to the end of the lunar March, and from September to late November. The low seasons occur around the Dragon Boat Festival and from late November onwards [4] - **DIP/DRG Pricing Standards**: The current DIP (Diagnosis-Related Group) and DRG pricing standards differ significantly from previous project reimbursement systems, allowing for more flexibility based on hospital levels. For instance, reimbursement for intraocular lenses in tertiary hospitals can reach 1,800 yuan, with total reimbursements up to 5,000 yuan [5][6] Market Dynamics of Intraocular Lenses - **Market Distribution**: The intraocular lens market is characterized by a normal distribution, with low-end products accounting for 20%-25%, high-end products for about 20%, and the remainder consisting of bifocal and other types. Cost control policies may lead to an increase in low-end products, while the choice of trifocal lenses will depend on pricing compliance with DIP standards [6][8] - **Low Penetration Rate**: China's cataract surgery penetration rate is lower than that of Europe and the US, attributed to limited insurance coverage, inadequate third-party payment systems, and a lack of public awareness regarding eye health. The average age for surgery is nine years later than the average onset age of the disease, indicating significant room for growth [7][9] Market Size and Future Projections - **Surgery Volume Growth**: The number of cataract surgeries in China has been gradually increasing, with projections of 430 million surgeries in 2023 and an expected 470-475 million in 2024. The target for 2025 is set at 490 million surgeries [2][10] - **Market Demand for Contact Lenses**: The demand for orthokeratology lenses is expected to grow by approximately 10% in 2025, with a total shipment of around 150 million lenses in the first five months of the year [16] Competitive Landscape - **Coexistence of Products**: Orthokeratology lenses and defocus glasses are expected to coexist in the market, catering to different consumer needs. While orthokeratology lenses are the most effective tool for myopia control, defocus glasses are gaining market share due to safety concerns among parents [19][20] Regulatory and Policy Implications - **Government Initiatives**: The government has established initiatives to improve cataract surgery penetration rates, but challenges remain due to limited insurance coverage and public awareness. It is anticipated that with increasing demand from the elderly population and ongoing policy support, penetration rates may gradually improve [9][18] Inventory and Pricing Dynamics - **Inventory Levels**: The inventory ratio for intraocular lenses is approximately 1:8, meaning for every 100 surgeries, 800 lenses are kept in stock. In contrast, orthokeratology lenses are ordered on a per-need basis, with no significant inventory maintained [22] - **Price and Margin Differences**: The pricing and profit margins for intraocular lenses and orthokeratology lenses in overseas markets are generally higher than in China, although domestic production costs are lower due to reduced R&D and intellectual property costs [23][24]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Haohai Biological Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of June 3, the company's stock closed at 53.32 yuan, with a rolling PE ratio of 30.09, marking a new low in 28 days, and a total market value of 12.434 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Haohai Biological at the 66th rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 619 million yuan, reflecting a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41% year-on-year, with a gross margin of 69.52% [1] - As of the Q1 2025 report, three institutions hold shares in Haohai Biological, with a total of 2.4635 million shares valued at 146 million yuan [1]

Summary of Aibo Medical Conference Call Company Overview - Aibo Medical started with artificial lens business and expanded into orthokeratology lenses and contact lenses, creating a diversified product matrix [2][4] - The company has achieved a compound annual growth rate (CAGR) of 49% in revenue and 64% in net profit from 2018 to 2024 [2][5] Revenue Structure - Artificial lenses remain the main source of revenue but are declining in proportion, expected to account for 42% of revenue in 2024 [2][6] - Orthokeratology lenses are projected to increase to 17% of revenue by 2024 [2][6] - Contact lenses have rapidly increased their revenue share to 30% by 2024 [2][6] Market Expansion - Aibo Medical is actively expanding its overseas market, with current overseas revenue accounting for about 3%-4% [2][7] - The company has established sales networks in Europe, Asia, and Oceania, with plans to further expand into South America [2][7] Industry Potential - The domestic cataract surgery penetration rate is significantly lower than that of developed countries, indicating substantial market potential for artificial lenses [2][8] - The domestic market for artificial lenses is expected to exceed 10 billion yuan by 2030 [2][8] Competitive Landscape - Aibo Medical is positioned as a leading domestic player in the artificial lens market, benefiting from the trend of domestic substitution due to centralized procurement [2][9] - The average price reduction from centralized procurement is around 60%, which is considered moderate [2][9] Innovation and Development - Aibo Medical has made significant technological breakthroughs in multi-focal artificial lenses, breaking the import monopoly [3][4] - The company has developed a strong product pipeline in the field of myopia prevention, with orthokeratology lenses becoming a key growth driver [10][12] Future Growth Expectations - Aibo Medical is expected to maintain steady growth, with profit growth projected to exceed 20% from 2025 to 2027 [2][15] - The company is anticipated to achieve revenues of approximately 4.7 billion yuan in 2025, 5.9 billion yuan in 2026, and 7.1 billion yuan in 2027 [2][15] Key Milestones in Myopia Prevention - The commercialization of orthokeratology lenses has progressed significantly since 2018, supported by policy, technological breakthroughs, and market promotion [10][11] Conclusion - Aibo Medical's diversified product offerings, strong market position, and innovative capabilities position it well for future growth in the ophthalmic medical device industry [2][15]